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Illumina microRNA arrayTumor metastasis continues to be themost signiﬁcant contributor to cancer related mortality, and although sev-
eral studies have examined expression proﬁles emanating frompatients withmetastatic disease, very little infor-
mation is available about signatures that differentiate metastatic lesions from primary tumors and associated
normal tissues, largely because such matched tissue sample series are rare. This study was speciﬁcally designed
to identify themetastasis relevantmicroRNAs in colorectal cancer and characterizemicroRNAs thatmodulate the
metastatic phenotype.Herewedescribe in detail how the data, deposited in theGene ExpressionOmnibus (GEO)
with the accession number GSE54088, was generated including the basic analysis as contained in themanuscript
published in Cancer Research with the PMID 26069251.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Speciﬁcationsrganism/cell
line/tissueHomo sapiens/colon and rectumx All male
quencer or array type The Illumina human miRNA Sentrix Universal Array
Matrix (SAM) V1 arrays
ata format Raw and analyzed
xperimental factors Tumor, normal, metastasis and background tissues
xperimental features UICC stage IV
onsent Informed consent and ethical approval obtained from
patients and ethical committee, respectively
mple source location UMMMannheim, GermanySa1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54088.2. Experimental design, materials and methods
2.1. Experimental design
Tissue samples from colorectal cancer patients comprising the pri-
mary tumor, adjacent normal tissue, resectedmetastasis and thenormalry, Medical Faculty Mannheim,
7, 68167Mannheim, Germany.
.de (H. Allgayer).
. This is an open access article underbackground tissue inwhich themetastasis occurredwere obtained from
and used for miRNA proﬁling (Fig. 1).
2.2. Materials and methods
2.2.1. Patient material
Tumor, metastasis, and corresponding normal and background
tissue samples of patients with colorectal cancer were stored and
obtained from the tumor bank of the Mannheim Medical Faculty,
University of Heidelberg, Germany. The biobank was approved by the
Ethical Committee of the Medical Faculty, University Hospital
Mannheim, and informed consent was obtained from patients or their
spouses when the former were deceased. Tissue sections and specimen
were prepared by pathologists prior to snap freezing and subsequent
storage in liquid nitrogen prior to sectioning. Biobanking and handling
of the tissues followed the BRISQ guidelines [1]. 20–30, 20 μm sec-
tions/sample (depending on tissue size) were made in a cryotome and
used for RNA extraction. All samples had at least 80% tumor cell content.
2.2.2. Patient characteristics
Nine patients in total were proﬁled, four with primary colonic
tumors and six with rectal tumors. One patient had a primary tumor
in both colon and rectumand accounts for the extrarectal tumor sample.
All patients had stage IV disease with distant metastasis to either the
liver or lung. 8 of these patients had additional mRNA proﬁling data
and were included in the subsequent analysis as published in [2]. An
overview of the patients is given in Table 1.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic representation of experimental ﬂow. RNA was extracted from primary
tumor, normal mucosa, and metastasis and background tissue of colorectal cancer
patients. Total RNA was subsequently processed for miRNA and mRNA proﬁling using
microarray platforms. The data presented in this manuscript is only for the miRNA data,
in which 9 patients were proﬁled, but one was dropped for subsequent comparative
analysis with the mRNA data.
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Total RNA, including small RNAs, was isolated using the miRNeasy
mini kit (Qiagen, Hilden, Germany) according to the manufacturer's in-
structions. Brieﬂy, the thin cryosections were homogenized by
vortexing in QIAzol lysis reagent followed by chloroform separation
and column puriﬁcation. RNA concentration was measured using the
Nanodrop spectrophotometer, and RNA quality was evaluated on
StdSens chips using lab-on-chip automated electrophoresis (BioRad,
Germany). Only samples with an RNA quality index (RQI) greater than
or equal to 7 were used for further downstream processing.2.2.4. In vitro transcription, ampliﬁcation, labeling and hybridization
In general, the Illumina human miRNA Sentrix Universal Array
Matrix (SAM) protocol was used. Brieﬂy, 200 ng total RNA was
polyadenylated with a PAP enzyme (Poly-A Polymerase) and then
reverse transcribed using biotinylated oligo-dT primers. The cDNA
templates were then hybridized with miRNA-speciﬁc oligos (MSOs)
and unbound oligos were washed away. After second-strand cDNA
synthesis and PCR ampliﬁcation with ﬂuorescently labeled primers,
the labeled products were hybridized and signals detected with the
Illumina BeadScan reader. For quality assurance purposes, control
samples were added and evaluated at the polyadenylation, ﬁrst strand
synthesis, hybridization ofmiRNA-speciﬁc oligos, second strand synthe-
sis, ﬂuorophore incorporation and array hybridization steps.Table 1
Bio-sketch of proﬁled patients.
Sr.
No
Anonymized IDs Age⁎ Gender Histology
1 P2 59 Male Adenocarcinoma
2 P4 76 Male Adenocarcinoma
3 P6 65 Male Adenocarcinoma
4 P7 65 Male Adenocarcinoma
5 P8 66 Male Adenocarcinoma
6 P8 66 Male Adenocarcinoma
7 P9 71 Male Adenocarcinoma
8 P10 49 Male Adenocarcinoma
9 P11 65 Male Adenocarcinoma
10 P12 50 Male Adenocarcinoma
⁎ Age at surgery in years.2.2.5. Data normalization
Quantile normalization was applied using all array data from the
experiment. Resulting data were log2 transformed.
2.2.6. Statistical analysis
Pairwise comparisons were performed to test differential miRNA
expression between paired samples. First, normal and tumor tissues
were compared. We selected the colon samples from the patient
wherewe had colon and rectum samples to get a design that was nearly
balancedwith respect to tumor site. Additional testswere performed for
colon and rectum samples separately. Paired tests for differences be-
tween pairs of metastasis and corresponding normal tissue in the liver
and lung were computed. Finally, we compared pairs of tumor samples
and corresponding metastases. This was done as well for distant-site
normal colorectal tissue samples corresponding to the primary tumor
of the respective patients.We then identiﬁed thosemiRNAs with signif-
icant differences in the comparison of metastasis taking the differences
between metastasis and the surrounding normal tissue into account. A
multiplicity adjusted signiﬁcance level of 5% was used in all compari-
sons. Venn diagrams were used to display comparatively the different
sets of signiﬁcant miRNAs. The statistical analyses were performed
using the approach described by Smyth [3]. Adjustment for multiple
testing was done by controlling the false discovery rate [4,5]. All
statistical analyses were performed within the R statistical software en-
vironment (R version 2.15.3) using the R/Bioconductor packages
beadarray [6], version 2.6.0, and limma, version 3.14.4. MicroRNAs
with an estimated fold change of ≥1.5 and adjusted p-value ≤ 0.1 were
considered for further evaluation.
3. Discussion
We have described here a very unique data set of patients with
advanced colorectal cancer in which primary tumor and metastasis
were evaluated alongside their corresponding normal samples. This
data set is further supported by additional clinical data that could be
exploited in deciphering clinical associations; however, the small
sample size limits this applicability. This data set has been used as a
source of hypothesis generation to discern and investigate microRNAs
that impact metastasis in colorectal cancer. The outcome of such analy-
ses has led to the generation of our recent manuscript [2].
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